EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

VEXAS Syndrome Complicated by Myelodysplastic Syndromes: A Report of Two Cases and Review of Therapeutic Challenges

Hao Liang, Wenqiang Xie, Zeguang Wu, Yuan Long, Zeyan Shi, Zhengfang Liu

Transfusion Medicine and Hemotherapy · 21.11.2026

DOI: 10.1159/tmh/aevag014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion Medicine and Hemotherapy, online erschienen am 21.11.2026. Verfasst von Hao Liang und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a refractory, autoimmune, inflammatory disease caused by somatic mutations in ubiquitin-like modifier activating enzyme 1 (UBA1) gene. It is characterized by systemic inflammatory responses and hematologic abnormalities. This case report describes two male patients with VEXAS syndrome coexisting with myelodysplastic syndrome (MDS). Both patients were treated with high-dose corticosteroids to control inflammatory responses. Patient 1 developed hemophagocytic lymphohistiocytosis after immunosuppressive therapy; azacitidine treatment was ineffective, and the patient eventually died of severe pneumonia. Patient 2 developed antiphospholipid syndrome with an increased proportion of ring sideroblasts. The patient received azacitidine combined with ruxolitinib, which partially improved the inflammatory symptoms and blood counts; however, transfusion dependence persisted. Patient 2 later developed persistent fever difficult to control and died. Although glucocorticoids reduce inflammation, patients often remain dependent on them. The hypomethylating agent, azacitidine, shows limited efficacy, whereas Janus kinase inhibitors such as ruxolitinib may improve inflammatory symptoms. These cases underscore the importance of early detection of UBA1 mutations and highlight the clinical challenges associated with VEXAS syndrome coexisting with MDS. Early multidisciplinary collaboration is thus essential, and further research is needed to develop effective therapeutic strategies.

Zitieren

APA

Liang, H., Xie, W., Wu, Z., Long, Y., Shi, Z., & Liu, Z. (2026). VEXAS Syndrome Complicated by Myelodysplastic Syndromes: A Report of Two Cases and Review of Therapeutic Challenges. Transfusion Medicine and Hemotherapy. https://doi.org/10.1159/tmh/aevag014

Vancouver

Liang H, Xie W, Wu Z, Long Y, Shi Z, Liu Z. VEXAS Syndrome Complicated by Myelodysplastic Syndromes: A Report of Two Cases and Review of Therapeutic Challenges. Transfusion Medicine and Hemotherapy. 2026. doi:10.1159/tmh/aevag014

BibTeX
@article{Liang2026,
  author = {Liang, Hao and Xie, Wenqiang and Wu, Zeguang and Long, Yuan and Shi, Zeyan and Liu, Zhengfang},
  title = {VEXAS Syndrome Complicated by Myelodysplastic Syndromes: A Report of Two Cases and Review of Therapeutic Challenges},
  journal = {Transfusion Medicine and Hemotherapy},
  year = {2026},
  doi = {10.1159/tmh/aevag014}
}
Kostenlos starten →